NPC2 (Niemann-Pick type C2) antibody is a research tool targeting the NPC2 protein, a key player in intracellular cholesterol trafficking. NPC2. a small soluble lysosomal protein, binds and transfers cholesterol to NPC1. facilitating its export from lysosomes. Mutations in the NPC2 gene cause Niemann-Pick disease type C (NP-C), a rare lysosomal storage disorder characterized by cholesterol and lipid accumulation, leading to neurodegeneration and organ dysfunction. Antibodies against NPC2 are widely used to study its expression, localization, and function in cellular models, clinical diagnostics, and disease mechanism research. They enable detection of NPC2 in Western blotting, immunohistochemistry, and immunofluorescence, helping assess protein levels in patient samples or experimental systems. Additionally, these antibodies contribute to evaluating therapeutic interventions targeting NP-C, such as substrate reduction therapies or chaperone drugs. Recent studies also explore NPC2's roles beyond cholesterol homeostasis, including immune regulation and cancer, expanding the antibody's applications. Commercial NPC2 antibodies are typically validated in human, mouse, or rat samples, with both monoclonal and polyclonal variants available. Proper controls remain essential due to potential cross-reactivity with unrelated proteins in immunoassays.